$THMA News
Last published 4y ago
- 4y agoTHMAPear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics CompanyBusiness WirePublicly traded company called Pear Therapeutics, Inc. to begin trading on Nasdaq under ticker symbol "PEAR" starting December 6, 2021 Total expected gross proceeds from transaction totaling approximately $175 million Pear Therapeutics,
- 4y agoTHMAPear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx ConferenceBusiness WirePear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednes
- 4y agoTHMAPear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use DisorderBusiness WirePear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administrati
- 4y agoTHMAPear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue GuidanceBusiness WirePear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today provides an update on significant progress in its commercialization, pipeline, and platform s
- 4y agoTHMAThimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business PlanBusiness WireIncreases minimum gross proceeds from PIPE and Sponsor to $175 million Removes minimum cash as a condition to the closing of the business combination PIPE Investors have agreed to lock-up 82.4% of the PIPE shares Today, Thimble Point Acquisitio
- 5y agoTHMAPear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product ListBusiness WirePear's prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List, effective November 1, 2021 MassHealth is now covering reSET and
- 5y agoTHMAPear Therapeutics to Participate in the BTIG Digital Health ForumBusiness WirePear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced management's participation in the virtual BTIG Digital Health Forum being held on Monday, November 1
- 5y agoTHMAPear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business CombinationBusiness WireSpecial meeting of Thimble Point Acquisition (NASDAQ:THMA) shareholders to approve the proposed business combination scheduled for November 23, 2021 at 9:00 a.m. Eastern Time Upon Closing, the Combined Company will trade on the NASDAQ under the
- 5y agoFBINGNTHMAPear and Thimble Point Announce Nominees to Board of DirectorsBusiness WireKirthiga Reddy, Partner at SoftBank Investment Advisers, and Alison Bauerlein, co-founder, Chief Financial Officer and Executive Vice President of Finance at Inogen, are nominees to become directors of Thimble Point Acquisition Corp. (NASDAQ:THMA), wh
- 5y agoBCYPGSAHSNNYTHMAMoore Kuehn Encourages SNNY, GSAH, THMA and BCYP Investors to Contact Law FirmGlobeNewswireNEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 5y agoTHMAPear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital TherapeuticsBusiness WirePear Therapeutics, Inc. ("Pear") has built the first end-to-end platform for prescription digital therapeutics (PDTs), which are FDA-authorized, clinician-prescribed, and payor-reimbursed software that directly treats serious diseases Business
- 5y agoJWSSPFRAVANAJAX+2Family Offices Are Targeting 800% Returns With SPAC EconomicsBloomberg